Expression IRF/MUM125% Predictor to Three-year Survival of Diffuse Large B Cell Lymphoma in the Immunochemotherapy Era
| Autor: | Emina Suljovic Hadzimesic, Alma Sofo-Hafizovic, Refet Gojak, Adisa Chikha |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Oncology
Adult Male medicine.medical_specialty Pathology Adolescent 030204 cardiovascular system & hematology 03 medical and health sciences Young Adult 0302 clinical medicine Immunophenotyping hemic and lymphatic diseases Internal medicine medicine Humans 030212 general & internal medicine Prospective Studies Young adult B-cell lymphoma Prospective cohort study Survival rate Aged Retrospective Studies Original Paper business.industry Retrospective cohort study General Medicine Middle Aged medicine.disease MUM1 expression Survival Rate Treatment Outcome DLBCL Interferon Regulatory Factors three-year survival Immunohistochemistry Female Immunotherapy Lymphoma Large B-Cell Diffuse business Diffuse large B-cell lymphoma |
| Zdroj: | Medical Archives |
| ISSN: | 0350-199X |
| Popis: | Introduction: Non Hodgkin lymphoma-Diffuse large B cell lymphoma (DLBC) is composed of more varieties of one disease. Analysis and understanding of a wide range of characteristics of the disease, which include: clinical, immunohistochemical, cytogenetic and molecular characteristics may improve treatment results. Aim: achieving the estimated three-year survival and influence of IRF/MUM1 expression to three-year survival. Material and methods: A study was retrospective–prospective, patients were followed for seven years a period of dine. The study included 60 patients de novo DLBCL. Age was 18-72 years old, the average age 45 years, male 31 (51,7%) and female 29 (48.3%). Median follow-up was 47 months (3-91 months). To determine differentiation immunophenotype antibodies those were used anti-CD20, anti-CD10, anti-Bcl-6, IRF-4/MUM1, CD 138. Results: Included the GCB type was 65%. Impact prognostic index IPI>2 GBC vs non GBC p=0,038 X2. Statistically significant difference was confirmed compared to the IPI> 2 to 3 year OS p25% has the greatest impact on the disease outcome – three-year survival. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|